Loading...

China Isotope & Radiation Corporation

1763.HK•HKSE
Healthcare
Medical - Devices
HK$18.96
HK$0.75(4.12%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, China Isotope & Radiation Corporation achieved steady financial progress, growing revenue from $3.53B in Q4 2022 to $2.81B in Q2 2024. Gross profit stayed firm with margins at 52% in Q2 2024 versus 56% in Q4 2022. Operating income totaled $409.43M in Q2 2024, maintaining a 15% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $526.21M. Net income dropped to $154.50M, with EPS at $0.48. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;